Noemí Álvarez

Noemí Álvarez

Auto-generated profile, based on publicly available information

Noemí Álvarez

Hospital 12 de Octubre, Madrid, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RCRafael Colmenares
Rafael Colmenares
NÁNoemí Álvarez
Noemí Álvarez
SBSantiago Barrio
Santiago Barrio
Joaquin Martinez-LopezJoaquin Martinez-Lopez
Joaquin Martinez-Lopez
RAROSA AYALA
ROSA AYALA
The study of cell-free DNA (cfDNA) and other peripheral blood components (known as “liquid biopsies”) is promising, and has been investigated especially in solid tumors. Nevertheless, it is increasingly showing a greater utility in the diagnosis, prognosis, and response to treatment of hematological malignancies; in the future, it could prevent invasive techniques, such as bone marrow (BM) biopsies. Most of the studies about this topic have focused on B-cell lymphoid malignancies; some of them have shown that cfDNA can be used as a novel way for the diagnosis and minimal residual monitoring of B-cell lymphomas, using techniques such as next-generation sequencing (NGS). In myelodysplastic syndromes, multiple myeloma, or chronic lymphocytic leukemia, liquid biopsies may allow for an interesting genomic representation of the tumor clones affecting different lesions (spatial heterogeneity). In acute leukemias, it can be helpful in the monitoring of the early treatment response and the prediction of treatment failure. In chronic lymphocytic leukemia, the evaluation of cfDNA permits the definition of clonal evolution and drug resistance in real time. However, there are limitations, such as the difficulty in obtaining sufficient circulating tumor DNA for achieving a high sensitivity to assess the minimal residual disease, or the lack of standardization of the method, and clinical studies, to confirm its prognostic impact. This review focuses on the clinical applications of cfDNA on the minimal residual disease in hematological malignancies.

1 September 2021 in Leukemia Research
Verified
Journal Article
Closed access
NÁNoemí Álvarez
Noemí Álvarez
ARAlba Rodríguez-García
Alba Rodríguez-García
MMMaría Luz Morales
María Luz Morales
MGMiguel Gutiérrez
Miguel Gutiérrez
MMMarta Montero
Marta Montero
RAROSA AYALA
ROSA AYALA

29 June 2023 in medRxiv
Verified
Preprint
Open access
PDF file
JSJuan A. Delgado Sanchis
Juan A. Delgado Sanchis
PPPedro Pons-Suñer
Pedro Pons-Suñer
NANoemi Alvarez
Noemi Alvarez
CSClaudia Sargas
Claudia Sargas
SDSara Dorado
Sara Dorado
EGEVA BARRAGAN GONZALEZ
EVA BARRAGAN GONZALEZ
Background and Objective: The main objective in this paper is to validate a machine-learning model trained to predict the 90-day risk of complications for patients with Acute Myeloid Leukemia using variables available at diagnosis. This is a first fundamental step towards the development of a tool that could help physicians in their therapeutic decisions. Methods: 266 patients and 36 variables form the training dataset collected by Hospital 12 de Octubre (Madrid, Spain). The external test cohort provided by Instituto de Investigación Sanitaria La Fe (Valencia, Spain) contains 162 observations. An XGBoost model was trained with one dataset and validated with the other. Additionally, the features were ranked by permutation importance and compared with the ELN 2022 risk classification by genetics at initial diagnosis. Results: The model was evaluated with the training cohort using leave-one-out cross-validation, reaching a ROC-AUC of 0.85. By setting the functioning point that maximises Youden’s index, 3 out of 4 patients with complications and 84 out of 100 in remission are correctly classified. The model was validated with external data collected in a different hospital, achieving 0.7 ROC-AUC. At the best functioning point, almost 6 out of 10 patients with complications and 8 out of 10 patients in remission are correctly classified. Ranking the variables by descending importance, the top four are, in order: age, white-blood-cells count, Gender, and TP53. The list exhibits good coherence with the ELN 2022 risk classification. Conclusions: The model achieves performances that suggest it could be used as a therapeutical decision support tool. Important variables are coherent with ELN 2022 risk classification. Further work is needed to understand the reasons for the drop in test performance. The 90-day model should be supplemented by others that predict the risk of complications at six months or one year.